Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.
Schrock AB, Frampton GM, Herndon D, Greenbowe JR, Wang K, Lipson D, Yelensky R, Chalmers ZR, Chmielecki J, Elvin JA, Wollner M, Dvir A, -Gutman LS, Bordoni R, Peled N, Braiteh F, Raez L, Erlich R, Ou SH, Mohamed M, Ross JS, Stephens PJ, Ali SM, Miller VA.
Schrock AB, et al. Among authors: bordoni r.
Clin Cancer Res. 2016 Jul 1;22(13):3281-5. doi: 10.1158/1078-0432.CCR-15-1668. Epub 2016 Mar 1.
Clin Cancer Res. 2016.
PMID: 26933124